Scleroderma renal crisis and renal involvement in systemic sclerosis (Q38957950)

8 September 2017

1 reference

title

Scleroderma renal crisis and renal involvement in systemic sclerosis. (English)

1 reference

8 September 2017

Thasia G Woodworth

1

1 reference

8 September 2017

Yossra A Suliman

series ordinal

2

1 reference

8 September 2017

Daniel E Furst

series ordinal

3

1 reference

8 September 2017

Philip Clements

series ordinal

4

1 reference

8 September 2017

language of work or name

English

0 references

publication date

19 September 2016

1 reference

Nature Reviews Nephrology

8 September 2017

published in

1 reference

8 September 2017

volume

12

1 reference

8 September 2017

issue

11

1 reference

8 September 2017

page(s)

678-691

1 reference

Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Incidence and prevalence of systemic sclerosis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal manifestations of systemic sclerosis--clinical features and outcome assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Longitudinal study of renal function in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal complications and scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Factors predicting development of renal involvement in progressive systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma renal crisis: patient characteristics and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal function is mostly preserved in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal disease in systemic sclerosis with normal serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Resistive intrarenal index: myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Long-term outcomes of scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Endothelin-1 expression in scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Association of RNA polymerase III antibodies with scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Endothelin axis polymorphisms in patients with scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Normotensive renal failure in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma associated with ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Efficacy of remission-induction regimens for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

The association of Raynaud syndrome with β-blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Endothelin receptor antagonism-based treatment for scleroderma renal crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Endothelin and endothelin antagonists in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

New therapies for diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Evolving importance of kidney disease: from subspecialty to global health burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

N-TproBNP as biomarker in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

End-stage kidney disease due to scleroderma--outcomes in 127 consecutive ANZDATA registry cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal transplantation in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma Renal Crisis: A Pathology Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal functional reserve in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

31 March 2020

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Prognosis of scleroderma renal crisis: a long-term observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Vasculitis in Systemic Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Clinical course of patients with scleroderma renal crisis treated with captopril

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Prazosin for Raynaud's phenomenon in progressive systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Hypertension After Kidney Transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2016.124

Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy

31 March 2020

1 reference

12 December 2020

An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes—Methodology and Preliminary Results

1 reference

12 December 2020

Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review

1 reference

12 December 2020

Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases

1 reference

12 December 2020

Scleroderma--clinical and pathological advances

1 reference

12 December 2020

Cytodiagnosis of granulocytic sarcoma presenting as superior vena cava syndrome in acute myeloblastic leukemia. A case report

1 reference

12 December 2020

Kidney disease other than renal crisis in patients with diffuse scleroderma

1 reference

12 December 2020

Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis

1 reference

12 December 2020

Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2016.124

1 reference

8 September 2017

1 reference